Xeris Pharmaceuticals | XERS - Ebitda

Stock Price
6.24
Daily Change
-0.14 -2.19%
Monthly
1.96%
Yearly
27.87%
Q2 Forecast
6.11

Xeris Pharmaceuticals reported $25.09M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Celltrion KRW 17.79B 356.77B Dec/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Organigram Holdings CAD 5.26M 884K Dec/2025
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pharma Mar EUR 2.71M 42.25M Mar/2026
Qiagen NV USD 249.69M 56.53M Dec/2025
Sartorius EUR 267.3M 10.1M Mar/2026
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
Tilray USD 8.36M 1.82M Sep/2025
Zealand Pharma A/S -727.47M 285.54M Dec/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M Mar/2026